Novel Natural History Study to answer question in Rare Disease
The Natural History Study of the rare lysosomal disease alpha-Mannosidosis will answer the question; why the rare disease develops as it does? The first patients have been included in the first Natural History Study of the disease, being conducted under the HUE-MAN project, a 6th framework, EU grant supported initiative.
Santaris Pharma consortium awarded €1.35m by Denmark’s Advanced Technology Foundation for development of the first microRNA medicine
Santaris Pharma announced today that the Danish National Advanced Technology Foundation (ATF) has awarded a grant of €1.35 million towards the development of the first ever drug targeted against a human microRNA.
The drug candidate, SPC3649, is an antagonist of the liver-specific microRNA-122 and is being developed by Santaris in collaboration with the Centre for Biological Sequence Analyses at the Technical University of Denmark and the Department of Cellular and Molecular Medicine, University of Copenhagen.
Ingredient maker Chr Hansen is set to begin large-scale tests on a new technology that could result in more robust and longer lasting probiotic bacteria, the firm announced last week.
The move could result in a new generation of probiotics suitable for a wide range of products, from dairy through to cereal and snacks.
New, groundbreaking technology may lead to a new generation of healthy dairy products
Chr. Hansen’s scientists see interesting potential in new, unique fermentation technology which improves conditions for “friendly” gut bacteria.
Yoghurts, soft drinks or juices with many more of the “friendly” gut bacteria (probiotics) with higher longevity and improved health effects – superior fermented dairy products or new developments within functional foods, we can’t even imagine today. These are some of the interesting prospects, Chr. Hansen researchers and technicians are facing with the help from this new technology.
The agreement with Chr. Hansen, a leading manufacturer of food ingredients, demonstrates commercial viability of Jurag Separations unique separation system and confirms the technology’s attractiveness for scalable and productive solutions in industrial settings.
With the joint venture Chr. Hansen gets access to Jurag Separations patented REED filtration technology, which offers advanced electro-membrane solutions for separation of ionic species directly from fermentation broth as well as from a variety of other complex process streams.